Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Samsung Bioepis Initiates Novel Drug Development for Rare Diseases

Mar 24, 2024

On 24 March 2024, the Korea Economic Daily (KED) reported Samsung Bioepis entered pre-clinical stage, with multiple undisclosed gene therapy candidates, for the treatment of rare diseases.

According to KED, Samsung Bioepis is committed to advancing drug development through the utilization of antibody-drug conjugates (ADCs), and by next year it intends to submit an investigational new drug (IND) application to initiate a phase 1 clinical trial, with a focus on rare diseases such as liver and metabolic disorders.